3.2 TAC exposure after lung transplantation
The average TAC C0 was 8.8 (IQR, 8.1–9.9) ng/mL, 8.5 (IQR, 7.7–9.8) ng/mL, and 7.8 ± 1.5 ng/mL for the epochs 0–3 months, 3–12 months and 12–24 months, respectively; whereas the corresponding TAC IPV were 36.7% (IQR, 30.2%–44.3%), 30.6% (IQR, 23.5%–39.0%), and 28.2% (IQR, 21.8%–35.0%) over the same corresponding period (Figure 1). Both parameters exhibited a descending trend over time.
The number of TAC C0 measurements for the periods 0–3 months, 3–12 months and 12–24 months were 18 (IQR, 14–21), 30 (IQR,12–29), and 13 (IQR,7–21), respectively (Figure 1). Patients received more extensive monitoring in the early post-transplantation periods, especially in the first year.
Given that CYP3A5 is the primary enzyme responsible for TAC metabolism, we sought to investigate its potential impact on TAC exposure; the results are summarized in Table S1. Notably, significant difference was observed only during the 0–3 months period between CYP3A5 expressers and non-expressers (P = 0.011 for TAC C0, P = 0.003 for TAC IPV).